Navesta Pharmaceuticals

navesta.com

Accessibility of high-quality pharmaceuticals are vital for communities to be built, economies to be developed, and the world to progress. Located in Sri Lanka, Navesta Pharmaceuticals is the country's leading privately owned pharamceutical manufacturer. Specialized in the manufacturing of dry powder Beta Lactam injectables (antibiotics), Navesta’s investment into its facilities and people ensure the highest quality products while the company’s commitment to the future generations of the world assure that anyone, anywhere, has access to life saving pharmaceuticals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

PharmaNewsIntelligence | March 11, 2020

news image

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

news image

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More

DON'T CUT BACK ON ASTHMA MEDS DURING PANDEMIC, EXPERT ADVISES

Drugs | April 19, 2020

news image

Despite increased demand for inhalers in some parts of the United States, Americans with asthma shouldn't ration their medications during the coronavirus pandemic, the American Lung Association says. Rescue inhalers are in short supply in some areas because hospitals are giving albuterol to COVID-19 patients with severe symptoms to help them breathe, the group explained. Albuterol is a quick-relief medication used to treat shortness of breath and wheezing in people with asthma and some other...

Read More

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

news image

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More
news image

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

PharmaNewsIntelligence | March 11, 2020

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More
news image

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More
news image

DON'T CUT BACK ON ASTHMA MEDS DURING PANDEMIC, EXPERT ADVISES

Drugs | April 19, 2020

Despite increased demand for inhalers in some parts of the United States, Americans with asthma shouldn't ration their medications during the coronavirus pandemic, the American Lung Association says. Rescue inhalers are in short supply in some areas because hospitals are giving albuterol to COVID-19 patients with severe symptoms to help them breathe, the group explained. Albuterol is a quick-relief medication used to treat shortness of breath and wheezing in people with asthma and some other...

Read More
news image

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us